Physician profile
Padamjit K Singh
NPI 1093754632
$21,809.84
in general payments reported to CMS, 2019-2025
32 companies · $5,068 in 2025
The $5,068 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $1,386 · 2021: $1,729 · 2022: $1,315 · 2023: $2,454 · 2024: $9,371 · 2025: $5,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $4,019 · Travel and Lodging: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,750.00 |
| Food and Beverage | $4,018.94 |
| Travel and Lodging | $124.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14,270.11 | 2019-2025 | Repatha, Repatha, Evenity |
| Nestle Healthcare Nutrition INC. | $1,453.51 | 2020-2023 | |
| Abbvie INC. | $945.43 | 2019-2025 | Vraylar, Linzess, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $859.93 | 2019-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $485.97 | 2022-2025 | |
| Lilly USA, LLC | $449.26 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Aimmune Therapeutics, INC. | $423.52 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $387.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $334.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.25 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.83 | 2019-2023 | Xifaxan |
| Ibsa Pharma INC. | $190.63 | 2019-2024 | Licart, Flector, Tirosint |
| Arbor Pharmaceuticals, INC. | $178.42 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $166.95 | 2020-2022 | |
| Pfizer INC. | $160.72 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $141.07 | 2024-2025 | Tymlos |
| Vivus LLC | $136.13 | 2021-2025 | Pancreaze |
| Glaxosmithkline, LLC. | $113.85 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $91.80 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $88.36 | 2022-2025 | Adthyza, Horizant, Edarbi |
| Exact Sciences Corporation | $74.22 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $68.73 | 2019-2021 | |
| Horizon Therapeutics Plc | $58.67 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $48.12 | 2020 | |
| Ironwood Pharmaceuticals, INC | $38.61 | 2019-2021 | |
| Inspire Medical Systems, INC. | $37.66 | 2024-2025 | Inspire |
| Abbott Laboratories | $23.15 | 2023 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $17.35 | 2020 | |
| Qol Medical, LLC | $15.11 | 2023 | Sucraid |
| Corcept Therapeutics | $14.61 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $11.34 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padamjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.